142 related articles for article (PubMed ID: 28498418)
1. Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.
He R; Yang N; Zhang P; Liu J; Li J; Zhou F; Zhang W
Oncol Rep; 2017 Jun; 37(6):3235-3243. PubMed ID: 28498418
[TBL] [Abstract][Full Text] [Related]
2. MMSA-1 expression pattern in multiple myeloma and its clinical significance.
Meng S; Lu C; Zhang W; Shen W; Wei Y; Su D; Zhou F
Clin Exp Med; 2016 Nov; 16(4):599-609. PubMed ID: 26493349
[TBL] [Abstract][Full Text] [Related]
3. [Immunological screening for multiple myeloma-associated antigens and their bioinformatics analysis].
Zhou FL; Zhang WG; Chen G; Zhao WH; Cao XM; Chen YX; Tian W; Liu SH; Wu MX; Liu M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):252-7. PubMed ID: 16638191
[TBL] [Abstract][Full Text] [Related]
4. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
Lu C; Meng S; Jin Y; Zhang W; Li Z; Wang F; Wang-Johanning F; Wei Y; Liu H; Tu H; Su D; He A; Cao X; Zhou F
Br J Haematol; 2017 Aug; 178(3):413-426. PubMed ID: 28508448
[TBL] [Abstract][Full Text] [Related]
5. Serological identification and bioinformatics analysis of immunogenic antigens in multiple myeloma.
Zhou FL; Zhang WG; Chen G; Zhao WH; Cao XM; Chen YX; Tian W; Liu J; Liu SH
Cancer Immunol Immunother; 2006 Aug; 55(8):910-7. PubMed ID: 16193335
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
[TBL] [Abstract][Full Text] [Related]
7. [The research on the expression and localization of multiple myeloma associated antigen MMSA-1].
Meng S; Zhou FL; Zhang WG; Cao XM; Wang BY; Wang Y; Bai GG
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Jan; 28(1):63-6. PubMed ID: 22230506
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
9. Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma.
Gupta R; Kaur G; Kumar L; Rani L; Mathur N; Sharma A; Dahiya M; Shekhar V; Khan S; Mookerjee A; Sharma OD
Ann Hematol; 2018 Dec; 97(12):2447-2454. PubMed ID: 30056581
[TBL] [Abstract][Full Text] [Related]
10. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
11. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
13. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
14. [Expression of
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):769-776. PubMed ID: 37356938
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
[TBL] [Abstract][Full Text] [Related]
17. [Expression and Clinical Significance of MMSA-8 and MMSA-1 in Bone Marrow of Patients with M2 Acute Myeloid Leukemia].
Liang Y; Yang AY; Liu M; Cheng YJ; Zang SB; Huang J; Tang YY; Huang ZP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1018-1021. PubMed ID: 35981356
[TBL] [Abstract][Full Text] [Related]
18. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
19. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
20. [Expression and Clinical Significance of C/EBPα Gene in Elderly Multiple Myeloma].
Zang YZ; Chen XL; Bai YL; Zhang WH; Yu RH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):123-128. PubMed ID: 30738458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
